Multidrug therapy of Mycobacterium avium subsp. avium infection in experimentally inoculated budgerigars (Melopsittacus undulatus)

• Published in: Avian pathology 2015-11, Vol.44 (6), p.470-474
• Main Authors: Ledwoń, A., Dolka, I., Dolka, B., Cegiełkowska, M., Czopowicz, M., Szeleszczuk, P.
• Format: Article
• Language: English
• Subjects: Animals; Anti-Bacterial Agents - therapeutic use; Clarithromycin - therapeutic use; DNA fingerprints; Drug Therapy, Combination; Epidemiology; Ethambutol - therapeutic use; Female; Fluoroquinolones - therapeutic use; Galliformes - microbiology; Genetic diversity; Genotype & phenotype; Male; Melopsittacus - microbiology; Mycobacterium avium - drug effects; Salmonella; Tuberculosis, Avian - drug therapy; Tuberculosis, Avian - microbiology; Tuberculosis, Avian - pathology
• ISSN: 0307-9457; 1465-3338
• DOI: 10.1080/03079457.2015.1086973

The aim of the study was to determine whether the four-month experimental therapy of mycobacteriosis in budgerigars may cause a complete recovery. A group of nine budgerigars was infected with a Mycobacterium avium subsp. avium isolate with proven pathogenicity for budgerigars. Five weeks post-inoculation, multidrug therapy was started. Another group comprising six birds received the same treatment but no infection, and the third group also comprising six birds was kept without infection or treatment as a control. The adopted antibiotic regimen included clarithromycin 61 mg/kg b.w., moxifloxacin 25 mg/kg b.w. and ethambutol 60 mg/kg b.w. administered by crop gavage every 12 h for 18 weeks. Despite a significant improvement in the condition of the infected, treated birds, the four-month therapy was not sufficient for the complete recovery of all.